Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-2879PMID 21402714PMCID PMC3108904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

  2010cited by this paper
• Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State*

  2009cited by this paper
• Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects

  2009cited by this paper
• Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

  2009cited by this paper
• The low‐affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo

  2009cited by this paper
• Dasatinib induces a response in chronic lymphocytic leukemia.

  2009cited by this paper
• c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

  2008cited by this paper
• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

  2008cited by this paper
• Pseudohyperkalemia in chronic lymphocytic leukemia.

  2008cited by this paper
• The effect of FK506 on transforming growth factor β signaling and apoptosis in chronic lymphocytic leukemia B cells

  2008cited by this paper
• The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia.

  2008cited by this paper
• Constitutive Activation of the Protein Tyrosine Kinase Syk in Chronic Lymphocytic Leukemia B-Cells.

  2007cited by this paper
• ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.

  2007cited by this paper
• The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia

  2006cited by this paper
• CATERPILLER 16.2 (CLR16.2), a Novel NBD/LRR Family Member That Negatively Regulates T Cell Function*

  2005cited by this paper
• Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

  2005cited by this paper
• Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

  2005cited by this paper
• Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2

  2005cited by this paper
• B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia.

  2005cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms.

  2004cited by this paper
• Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

  2004cited by this paper
• NF- kappa B2/p100 induces Bcl-2 expression.

  2003cited by this paper
• Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma

  2002cited by this paper
• Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

  2002cited by this paper
• Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Clinical trials referral resource. Clinical trials with perillyl alcohol.

  1997cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2

  1994cited by this paper
• Clinical trials referral resource.

  1990cited by this paper
• T-cell function.

  1984cited by this paper

• Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

  2025cites this paper
• B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

  2024cites this paper
• Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.

  2024cites this paper
• Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome

  2022cites this paper
• Imaging-based coculture model for high-throughput compound screening in hematological cancers

  2022cites this paper
• Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients

  2021cites this paper
• In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia

  2021cites this paper
• Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

  2020cites this paper
• Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies

  2020cites this paper
• TARGETING THE MALIGNANT B CELL MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2019cites this paper
• CLL and CML sometimes meet and circulate together

  2019cites this paper
• Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis

  2019cites this paper
• New roles for B cell receptor associated kinases: when the B cell is not the target

  2019cites this paper
• Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

  2018cites this paper
• The Role of STAT3 in the Pathogenesis of Chronic Lymphocytic Leukaemia

  2018cites this paper
• Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

  2018cites this paper
• NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy

  2018cites this paper
• Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies

  2018cites this paper
• Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia

  2018cites this paper
• Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment

  2017cites this paper
• Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

  2017influential citation
• Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro

  2017cites this paper
• Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.

  2017cites this paper
• Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas

  2017cites this paper
• NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

  2017cites this paper
• NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.

  2016cites this paper
• Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib

  2016cites this paper
• Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

  2016cites this paper
• Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.

  2016cites this paper
• Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets

  2016cites this paper
• Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents

  2016cites this paper
• Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.

  2016cites this paper
• Caractérisation des lymphocytes B régulateurs dans la leucémie lymphoïde chronique

  2016cites this paper
• High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

  2016cites this paper
• TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia

  2016cites this paper
• A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia

  2016cites this paper
• Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

  2015cites this paper
• Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.

  2015cites this paper
• Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.

  2015cites this paper
• Patologi Targeting chronic lymphocytic leukemia cells using anti-ROR 1 monoclonal antibodies and small molecule inhibitors

  2015cites this paper
• Emerging therapies for refractory chronic lymphocytic leukemia

  2015cites this paper
• Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

  2015cites this paper
• The targeting of human and mouse B lymphocytes by dasatinib.

  2015cites this paper
• Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

  2015cites this paper
• Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions

  2015cites this paper
• CME Information: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

  2015cites this paper
• Management of chronic lymphocytic leukemia (CLL) in the era of B‐cell receptor signal transduction inhibitors

  2015cites this paper
• Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date.

  2015cites this paper
• Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide

  2015cites this paper
• Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.

  2015cites this paper
• Lymphocytes from chronic lymphocytic leukaemia undergo ABL1-linked amoeboid motility and homotypic interaction as an early adaptive change to ex vivo culture

  2014cites this paper
• Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

  2014cites this paper
• B-cell receptor signaling in lymphoid malignancies and autoimmunity.

  2014influential citation
• Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.

  2014cites this paper
• 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.

  2014cites this paper
• Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

  2014cites this paper
• Author ' s Accepted Manuscript Incorporating targeted agents into future therapy of CLL

  2014cites this paper
• BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future

  2014cites this paper
• Functional characterization of NLRC3

  2014cites this paper
• Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib

  2014cites this paper
• The B-cell receptor pathway: a critical component of healthy and malignant immune biology.

  2014cites this paper
• Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia

  2014cites this paper
• Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

  2014cites this paper
• B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

  2014cites this paper
• Personalized medicine in CLL: current status and future perspectives.

  2014cites this paper
• Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315

  2014cites this paper
• Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

  2014cites this paper
• Targeting Susceptible Signaling Pathways in Chronic Lymphocytic Leukemia

  2014cites this paper
• B-Cell Receptor Signaling Pathway: Mechanisms and Inhibitors

  2014cites this paper
• Signal Transduction Therapies for Treatment of Chronic Leukemias

  2014cites this paper
• Role of chemokines and their receptors in chronic lymphocytic leukemia

  2014cites this paper
• Multidimensional Single-Cell Analysis of BCR Signaling Reveals Proximal Activation Defect As a Hallmark of Chronic Lymphocytic Leukemia B Cells

  2014cites this paper
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

  2014cites this paper
• Hairy cell leukemia – immunotargets and therapies

  2014cites this paper
• treatment strategies Signaling the end of chronic lymphocytic leukemia: new frontline

  2014cites this paper
• Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

  2014cites this paper
• Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice

  2014cites this paper
• Does B Cell Receptor Signaling in Chronic Lymphocytic Leukaemia Cells Differ from That in Other B Cell Types?

  2014cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta‐analysis and clinical characterization

  2013cites this paper
• Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.

  2013cites this paper
• B-cell receptor signaling as a driver of lymphoma development and evolution.

  2013cites this paper
• The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.

  2013cites this paper
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

  2013cites this paper
• Signaling pathways in lymphoma: pathogenesis and therapeutic targets.

  2013cites this paper
• Targeting inflammatory pathways in chronic lymphocytic leukemia.

  2013cites this paper
• Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.

  2013cites this paper
• Novel Bruton’s tyrosine kinase inhibitors currently in development

  2013cites this paper
• Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma

  2013influential citation
• Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

  2013cites this paper
• Precision medicines for B‐cell leukaemias and lymphomas; progress and potential pitfalls

  2013influential citation
• Critical signal transduction pathways in CLL.

  2013cites this paper
• B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn

  2013cites this paper
• Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

  2013cites this paper
• Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

  2013cites this paper
• BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies

  2013influential citation
• Towards targeted therapy of chronic lymphocytic leukemia.

  2013cites this paper
• INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA

  2013cites this paper
• Abstract 2886: Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of Chronic Lymphocytic Leukemia B cells.

  2013cites this paper
• Inhibitors of B-Cell Receptor Signaling for the Treatment of Chronic Lymphocytic Leukemia

  2013cites this paper